Northern Trust’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-40,812
| Closed | -$9.38K | – | 4518 |
|
|
2024
Q4 | $9.38K | Hold |
40,812
| – | – | ﹤0.01% | 4424 |
|
|
2024
Q3 | $87.7K | Hold |
40,812
| – | – | ﹤0.01% | 4090 |
|
|
2024
Q2 | $211K | Buy |
40,812
+3,915
| +11% | +$20.6K | ﹤0.01% | 3850 |
|
|
2024
Q1 | $197K | Sell |
36,897
-3,073
| -8% | -$21.2K | ﹤0.01% | 3898 |
|
|
2023
Q4 | $311K | Buy |
39,970
+13,576
| +51% | +$46.5K | ﹤0.01% | 3708 |
|
|
2023
Q3 | $104K | Buy |
26,394
+5,667
| +27% | +$21.2K | ﹤0.01% | 4005 |
|
|
2023
Q2 | $65.3K | Hold |
20,727
| – | – | ﹤0.01% | 4148 |
|
|
2023
Q1 | $55.3K | Buy |
20,727
+5,524
| +36% | +$21.4K | ﹤0.01% | 4243 |
|
|
2022
Q4 | $54.6K | Sell |
15,203
-3
| -0% | -$13 | ﹤0.01% | 4264 |
|
|
2022
Q3 | $98K | Buy |
15,206
+5,540
| +57% | +$45K | ﹤0.01% | 4120 |
|
|
2022
Q2 | $93K | Sell |
9,666
-39,042
| -80% | -$365K | ﹤0.01% | 4203 |
|
|
2022
Q1 | $579K | Sell |
48,708
-3,780
| -7% | -$67.6K | ﹤0.01% | 3683 |
|
|
2021
Q4 | $1.71M | Buy |
52,488
+20
| +0% | +$810 | ﹤0.01% | 3301 |
|
|
2021
Q3 | $2.35M | Sell |
52,468
-2,974
| -5% | -$145K | ﹤0.01% | 3205 |
|
|
2021
Q2 | $3.02M | Buy |
55,442
+3,451
| +7% | +$204K | ﹤0.01% | 3153 |
|
|
2021
Q1 | $3.89M | Buy |
51,991
+6,812
| +15% | +$708K | ﹤0.01% | 2900 |
|
|
2020
Q4 | $4.9M | Sell |
45,179
-1,005
| -2% | -$91.7K | ﹤0.01% | 2694 |
|
|
2020
Q3 | $4.08M | Sell |
46,184
-3,014
| -6% | -$342K | ﹤0.01% | 2655 |
|
|
2020
Q2 | $5.25M | Buy |
49,198
+8,464
| +21% | +$760K | ﹤0.01% | 2491 |
|
|
2020
Q1 | $2.42M | Buy |
40,734
+584
| +1% | +$39.6K | ﹤0.01% | 2750 |
|
|
2019
Q4 | $2.77M | Sell |
40,150
-2,535
| -6% | -$154K | ﹤0.01% | 2929 |
|
|
2019
Q3 | $4.43M | Buy |
42,685
+9,520
| +29% | +$899K | ﹤0.01% | 2621 |
|
|
2019
Q2 | $3.07M | Buy |
33,165
+2,520
| +8% | +$175K | ﹤0.01% | 2819 |
|
|
2019
Q1 | $2.8M | Buy |
30,645
+28
| +0.1% | +$1.95K | ﹤0.01% | 2885 |
|
|
2018
Q4 | $1.71M | Buy |
30,617
+218
| +0.7% | +$16.6K | ﹤0.01% | 3141 |
|
|
2018
Q3 | $3.62M | Buy |
30,399
+2,835
| +10% | +$329K | ﹤0.01% | 2884 |
|
|
2018
Q2 | $2.81M | Buy |
27,564
+9,455
| +52% | +$1.17M | ﹤0.01% | 3017 |
|
|
2018
Q1 | $2.35M | Buy |
18,109
+4,693
| +35% | +$513K | ﹤0.01% | 3016 |
|
|
2017
Q4 | $1.3M | Sell |
13,416
-210
| -2% | -$28.2K | ﹤0.01% | 3324 |
|
|
2017
Q3 | $2.01M | Buy |
13,626
+7,819
| +135% | +$1.47M | ﹤0.01% | 3173 |
|
|
2017
Q2 | $935K | Buy |
5,807
+2,497
| +75% | +$392K | ﹤0.01% | 3461 |
|
|
2017
Q1 | $527K | Buy |
3,310
+605
| +22% | +$73.8K | ﹤0.01% | 3515 |
|
|
2016
Q4 | $329K | Buy |
+2,705
| New | +$379K | ﹤0.01% | 3630 |
|
Other funds holding SYRS
BBA
1CM
Northern Trust's SYRS Position: Q1 2025 in Review
Northern Trust sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 40,812 shares — an estimated $9.38K sold.
Northern Trust first reported a position in SYRS in Q4 2016 and held it in 33 quarters. The position peaked at $5.25M in Q2 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Northern Trust reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Northern Trust sold 40,812 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $9.38K.
- Northern Trust first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 33 quarters.
- Northern Trust's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5.25M in Q2 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.